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ABSTRACT 
COMPARING THE SAFETY AND EFFICACY OF LOW DOSE MAGNESIUM 
SULPHATE – DHAKA REGIME WITH PRITCHARD REGIME IN THE 
MANAGEMENT OF ECLAMPSIA 
AIMS 
 To study the safety and efficacy of low dose Magnesium Sulphate                
(Dhaka  Regime) in Eclampsia and to compare the maternal and perinatal 
outcome in Dhaka and Pritchard Regimes.  
 
METHODS 
 This is a Randomised  control study done during Jan 2011 to Jan 2012 
including 100 patients. 50 were treated under Pritchard Regimen in which a 
loading dose of 4 gm of 20% MgSO4 IV and 10 gms of 50% MgSO4 Im given. 
Maintenance dose was given as 5gm of 50% MgSO4 repeated at 4 hour 
intervals till 24 hours after the last fit or 24 hours after the delivery of fetus 
whichever is later.  
 50 Eclamptic patients were treated under Dhaka Regime in which 
loading dose of 4 gm of 20% MgSO4 IV and 6gms of 50% MgSO4 Im given 
and repeated  at 4 hourly intervals in which 2.5gm of 50 % MgSO4 given as 
maintenance dose. Recurrence of fits, maternal and perinatal outcome in both 
groups were compared.  
 
RESULTS AND ANALYSIS 
 Recurrence of fits was noticed in 2% each in Dhaka and Pritchard 
regime. The maternal mortality in this study is 2% each in Dhaka and Pritchard 
regimen. The cause of death in both patients were due to complications of 
Eclampsia. The perinatal mortality in Dhaka regimen is 20% and perinatal 
mortality in Pritchard regimen is 30%  
 
CONCLUSION 
 The low dose efficiency of MgSO4 – Dhaka regime is sufficient for the 
management of eclampsia and it is equivalent to the standard Pritchard 
regimen.  
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INTRODUCTION 
 
‘Eclampsia’ is a term  derived from  Greek word .It  means   flashing 
lights1. It is defined as the development of generalised tonic, clonic seizures 
during pregnancy (or) post partum in patients of preeclampsia in whom  
other causes cannot be attributed.2 
 
         It can occur as Antepartum eclampsia in 35-45%, Intra partum 
eclampsia   in   15-20%, Postpartum  eclampsia in  35-45%.3 
 
         Eclampsia is one of the deadly triad of Maternal Mortality.Eclampsia 
often, a manifestation of uncontrolled severe preeclampsia can be prevented.  
The maternal mortality is 1.8% and perinatal mortality rate is 80 per 1000 
births in eclampsia. 
 
Dr.J.A.Pritchard4 proposed a regimen for the management of 
convulsions in eclampsia in 1955  in Parkland Hospital. In 1975 he did an 
observational data in Kings Country Hospital in Brooklyn with MgSO4.  
Collaborative  Eclampsia Trial in 1995  compared  the efficiency of MgSO4, 
Diazepam, Phenytoin. It was concluded that MgSO4 is associated with   
decreased seizure  recurrence and decreased maternal  mortality. 
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In 1998 March to June, in Dhaka,5 capital of Bangladesh,                         
a prospective study including 65 patients of eclampsia treated with low dose  
Magnesium sulphate was conducted. It was concluded that the low dose 
MgSO4  which  is nearly  half  that of  Pritchard  was sufficient to control 
the  convulsion effectively in Eclampsia.  
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AIM 
 
 The safety and efficacy of low dose Magnesium Sulphate regime in 
the management of convulsion in Antepartum / Intrapartum / 
Postpartum eclampsia   patients. 
 
 This study also compares the maternal and perinatal outcome in 
patients treated with Pritchard and Dhaka regimen. 
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REVIEW OF LITERATURE 
 
DEFINITION: 
Eclampsia is defined as the onset of convulsions or coma in women 
who have either gestational  hypertension  or pre eclampsia.  Unfortunately 
in 15% cases, hypertension and proteinuria are absent.  However, when 
seizures develop in a pregnant women  without a known  history of  seizure 
disorder, Eclampsia should be the diagnosis until proved otherwise. 
 
INCIDENCE: 
In developed countries 1 in 2000 to 1 in 4000 deliveries is 
complicated by eclampsia . In developing countries 1 in 100 to 1 in  1700 
deliveries is complicated by eclampsia. 
 
TYPES OF ECLAMPSIA:  
Antepartum eclampsia --convulsion occurring before labor(35-45%) 
Intrapartum eclampsia – convulsion during  labor(15-20%) 
Post partum eclampsia – convulsion after  labor(35-45%) 
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ETIOLOGY :   
Though   many theories have been proposed for the etiology, It is still 
unclear. Eclampsia being an extreme degree of pre eclampsia, the 
biochemical changes and histo pathological changes are the same for both, 
except, that it is most pronounced in eclampsia.  
  Mechanisms currently proposed to explain the courses of eclampsia 
are culmination of maternal, placental and fetal factors.  
They are  
1) Implantation of placenta with abnormal trophoblast                                        
invasion of uterine vessels. There is incomplete  trophoblastic 
invasion  of spiral arterioles.  
Madzali and associates (2009)6 proved  that severity of 
hypertension is directly proportional to the magnitude of defective 
trophoblastic invasion. 
             
2) Maladaptive Immunological tolerance between maternal ,placenta    
and fetal tissues. There is immune tolerance from mother towards 
paternally derived placental and fetal antigens. This is proved by the 
occurrence of preeclampsia more in primigravida, high occurrence 
of preeclampsia in molar pregnancy, 30 to 40% incidence of 
preeclampsia in Trisomy 13. 
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3) Maladaptation  to cardiovascular and inflammatory changes of 
normal pregnancy     
4) Genetic factors 
5) Nutritional factors :  
It was reported by Zhang7 and associates (2002) that  if 
ascorbic acid intake is less than 85 mg  it is associated with pre 
eclampsia. 
Lots of fruits intake is associated with  low BP as shown by 
John8 and co workers in( 2006). 
Villar9 and associates (2002) proved that calcium supplementation 
has no beneficial role in the prevention of pre eclampsia. But 
supplementation of calcium reduces the perinatal  mortality. 
 
PATHOGENESIS  
1. Vasospasm: 
 In 1918 Volhard  put forward the concept of vasospasm based on the 
observation in small vessels of nail bed, fundus, and bulbar conjunctiva. 
Vasospasm cause increased resistance and subsequent hypertension. 
In  2002 Wang10 et al  demonstrated endothelial junctional protein 
disruption. Endothelial disintegrity causes interstitial leakage through which 
blood platelets and fibrinogen are deposited subendothelially. 
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  Suzuki et al11 (2003) explained the ultra structural changes in sub 
endothelial region of resistance arteries in pre eclamptic women. With 
reduced blood flow, there is ischemia of surrounding tissue leading  to 
necrosis, haemorrhage and other end organ damage. 
 
2. Endothelial cell activation: 
Anticoagulant property of intact endothelium is reversed on 
subendothelial activation  and increase the sensitivity to vasopressor.   
  In 2008 Grundmann12 and  associates  have found that circulating 
endothelial cell levels (CEC) are significantly elevated four fold in 
peripheral  blood of pre eclamptic  mothers.  
 
3. Increased Pressor  Response: 
In 1961 Abdul–karim13 Assali   reported that normally pregnant 
women have refractoriness to infused  vasopressors.  
 But in  preeclamptic women, they  have increased response to 
infused Nor adrenaline, Angiotensin  II   and it was reported by  Raab& 
coworkers in 1956.  
In 1974 Gant14 & colleagues  noticed   that  this refractoriness 
develop several weeks before the onset of hypertension.  
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4. Prostaglandins:  
Endothelial  prostaglandins   responsible  for vascular  refractoriness  
is  diminished (PGI2) .Similarly  ThromboxaneA2  secretion  by platelets is 
increased. Thus Prostacyclin : TX A2 ratio is decreased.   
These ultimately results in enhanced sensitivity to pressor agents and 
thereby cause vasoconstriction. 
 The above changes are evidenced in pre eclamptic women as early   
as  22 weeks of gestational age and the same was proved by Chavarria 15 & 
co  workers 2003.  
 
5. Nitric oxide  
Nitric oxide derived from L- arginine by endothelial cells is a potent 
vasodilator.  
 Myat16 et al in 1992 showed that Nitric oxide maintains the normal 
low pressure, vasodilator state characteristic of fetoplacental perfusion. 
Preeclampsia  is associated with decreased  endothelial  nitricoxide synthase 
expression thus increasing inactivation of nitric oxide. 
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6. Endothelins: 
Endothelin ET 1 – produced by human endothelium a potent 
vasoconstrictor is increased in normotensive in pregnant woman. In the 
preeclamptic woman, endothelins are much more increased.  
Sagsoz17 and kucukozkan in the year 2003 noticed that on 
administration of Magnesium sulphate, ET1  concentration is reduced.  
 
7. Angiogenic causes: 
Karumanchi18 and colleagues in 2009 found  that in women who are 
prone to develop pre eclampsia   produce minimum of  2 Anti Angiogenic 
peptides in maternal serum .They are 
 Soluble FMS- like tyrosine kinase 1 .(SFlt -1) : 
are elevated reducing  PIGF,VEGF thereby causing endothelial 
dysfunction. Maynard &associates 2003 has shown SFlt-1 will start 
rising many months before the clinical presentation of pre eclampsia. 
 Soluble  endoglin:   
Seng inhibits endoglin thereby prevents the binding of TGF β to the 
receptors in endothelium that causes NO thereby vasodilatation. Its 
level also starts rising months before clinical presentation of pre 
eclampsia as shown by Levine19 & coworkers in 2006. 
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Riskfactors  
1. Parity: 
Eclampsia affects more young and nulli parous women.Whereas 
chronic hypertension with superimposed pre eclampsia affects multiparous 
women. 
In 2009, Sibai20 and Cunningham reported that there is 3 to 10% 
incidence of preeclampsia in nulliparous women.  
 
2 .Genetic predisposition: 
Pre eclampsia is a multifactorial, polygenic disease. Ward and 
Lindheimer (2009)21 noticed that the risk for developing preeclampsia is                     
20 to 40%   in the daughters.  11 to 37% in their sisters.  
3. Environmental. 
4. Seasonal influences 
Occurs in winter and rainy season when there  is increased  humidity.  
5. Socio economic. 
6. BMI: 
The risk of pre eclampsia is directly proportional to weight gain 
In BMI > 35 kg/m2 the incidence is   13.3%   
In  BMI  -20kg/m2  the incidence was only  4.3%  
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Con de Agudelo22 &Belizan (2000) added other risk factors like  
 Multifetal gestation 
 Obesity  
 Maternal age more than 35 years.  
Getahun23 & colleagues (2007) found that the incidence of 
preeclampsia is lower in subsequent pregnancies in woman with normal 
blood pressure in their pregnancy. 
 
PATHOPHYSIOLOGY OF ECLAMPSIA  
As formulated by Borzychowski24 2006, and Redman25 2009 the 
theory of two  stage Disorder of pre eclampsia shows 
Stage I: is preclinical: There is faulty trophoblastic vascular 
remodelling of uterine arteries resulting in placental hypoxia. 
 Stage II: placental factors release into maternal circulation resulting  
in systemic  inflammatory  response and endothelial  activation.  
Preeclampsia is more likely to develop in women who are for the first 
time exposed to chorionic villi in pre existing renal or cardiovascular 
disease and genetically prone women. 
There is an imbalance in autoregulation of cerebrovascular system 
resulting in  intense vasospasm (or) vasodilatation. 
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If the response to hypertension is vasospasm, there is  
 ischemia, 
 cytotoxic edema, 
 tissue infarction. 
As Schwartz26 pointed out if the severe hypertension exceeds the 
normal regulatory capacity there is forceful vasodilatation causing   
extravasation of plasma and RBC through endothelial lining leading to 
vasogenic edema. 
Meldrum27 in 2002 reported that seizures are associated with excess 
release of excitatory neurotransmitters like Glutamate, burst of action 
potentials, large depolarization of network neurons. 
In woman who died due to eclampsia, their autopsy findings revealed 
 micro infarcts in cortical matter and white matter of brain 
 cerebral edema 
 cerebral parenchymal bleeding and 
 vascular lesions more in Occipital lobe. 
 
PRE MONITORY SYMPTOMS OF ECLAMPSIA: 
Head ache: 
It is due to hyperperfusion of brain especially Occipital lobe .since the 
anterior part of brain is  well supplied by sympathetic innervations, 
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Occipital lobe is much affected . 50 to 75% eclamptic mothers has 
preceding headache which is not relieved by analgesics. Headache is mild to 
severe, constant or intermittent and improves after initiating MgSo4 therapy. 
The headache is described as throbbing type. 
 
Visual disturbances:  
20 to 30% have disturbances in vision before onset of eclamptic 
seizures. The different visual disturbances are diplopia, blurred vision, 
scotoma. They are relieved on lowering the Blood pressure or after MgSo4 
therapy. The symptoms are due to  spasm of retinal arterioles, edema and 
retinal ischemia. 
1 to 3 % of eclamptic cases    have   reversible   blindness  arise from 
3 potential areas. 
Visual cortex of brain 
Lateral geniculate nuclei 
Retina : retinal ischemia,infarction,detachment 
It takes about 1 week for the blindness to get corrected after the 
delivery  of fetus. 
 
Changes in the mental status: 
Ranges from  lethargy, confusion,blurred vision to coma.  It occurs 
due to cerebral edema. 
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Right upper quadrant pain (or) epigastric pain: 
Due to stretching of  Glisson’s  capsule  due to edema or sub capsular 
haemorrhage, hepato cellular ischemia, necrosis. 
Vomiting  
 
Clinical stages of Eclampsia. 
There are 4 clinical phases in an attack of eclampsia. 
 
  1. Premonitory stage: 
The patient loses her consciousness. It is associated with twitching of 
facial muscles. It lasts for a period of less than  30 seconds. 
 
2. Tonic stage: 
It is associated with a spasmodic contraction of the entire body. It 
lasts for a period  of   15 to 30 seconds.The  whole body becomes rigid.arms  
are flexed.hands are clenched.  
 
3 Clonic stage 
It is associated with alternate contraction and relaxation of voluntary 
muscles. It lasts for approximately 1 minute. Tongue bite due to violent 
action on jaws. Then the intensity of the movement of muscles is reduced.           
The diaphragm becomes fixed during the seizures and there is no breathing. 
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Froth occurs in the mouth. After stertorous breathing the normal breathing 
recurs.  
 
4  Phase of Coma 
            The movements stops.Time duration is variable. 
 
DIFFERENTIAL DIAGNOSIS: 
 Epilepsy 
 Meningitis 
 Encephalitis 
 Tumour in Brain 
 Cysticercosis 
 Ruptured   cerebral aneurysm in late pregnancy and puerperium. 
 Cerebral malaria 
 Hysteria 
 
COMPLICATIONS OF ECLAMPSIA 
MATERNAL COMPLICATIONS 
1. Abruption   10% 
2. neurological sequelae -7% 
3. Aspiration pneumonitis -7% 
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4. Pulmonary edema -5% 
5. Acute Renal failure -4% 
6. HELLP  syndrome 4% 
7. Cardiac arrest 4% 
8. Maternal death 1% 
9. Maternl Injuries  
  Tongue bite 
 External injuries  -bruise,fractures 
 Asphyxia due to swollen tongue occluding glottis. 
10. Hyperpyrexia 
 
FETAL COMPLICATIONS : 
 IUGR 
 Prematurity 
 Asphyxia .  
The perinatal  mortality  and  morbidity is as high as 30-50%.   
Fetal bradycardia persist after a fits.It may persist for 3 to 5 minutes only. 
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MANAGEMENT OF ECLAMPSIA  
The principles in Management of eclampsia are  
1) Control of convulsion with  Inj.MgSO4 
2) Anti hypertensive medication  
3) Avoidance of diuretics and limitation of intravenous fluids since 
pre eclamptic patients have high hemoconcentration. 
4)  Termination of pregnancy to achieve a cure.  
 
SUPPORTIVE TREATMENT:   
It includes care of the patient in a quiet, noise  free room .  
Position of the patient should be in lateral decubitus. 
   Continuous monitoring  of the patient’s general condition 
 Pulse rate 
 Blood  pressure 
 Respiratory rate 
 Oxygen saturation. 
 Input/ output chart should be  maintained. 
Airway, Mouth gag  should be kept ready. Suction apparatus should 
be in the room for quick suctioning. 
 Tongue bite is prevented by a soft mouth gag in between 
teeth. 
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  Urinary catheter should be inserted for monitoring urine 
output. 
 All the blood investigations like Clotting Time, 
o Clot Retraction time, 
o Renal Function test, 
o Liver Function Test, 
o Complete Blood Count, 
o Peripheral Smear  are done.  
Thus complications  like  HELLP, DIC, Renal failure etc. are 
diagnosed. Cardio Vascular System, Respiratory System should be  
thoroughly examined 
Antibiotics should be given.  
One to one nursing care  should be given.  
 
CONTROL OF CONVULSIONS 
In the year 1955 Pritchard presented a paper regarding the 
management of eclampsia with magnesium sulphate. In 1990, the 
randomized trials of management of eclampsia were published. 
In 2002, MAGPIE28 trial  was conducted in about 10000  
preeclamptic patients. Patients  were randomly selected. They were divided 
into two groups and treated with MgSO4  in one group  and  another  with 
placebo .   
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It was found that in patients treated with MgSO4 had significantly 
58% lower risk for eclampsia than the placebo group.   1.9% had eclampsia 
in placebo group.But it was only 0.8% seizures in MgSO4 group.     
Before MgSo4 various anticonvulsants were used. The different 
regimens are  
1. Menon Regimen(1961) 
2. Lean Regimen 
3. Phenytoin    
 
MENON REGIMEN: 
This includes  IV administration of 25mg Chlorpromazine & 100mg 
Pethidine in 20ml of 5% glucose and IM  administration of 50mg 
Chlorpromazine & 25 mg Promethazine. The IM Injection of 
Chlorpromazine and  Promethazine are repeated at 4 hourly  intervals for 24 
hrs after the last fit. Menon also used Lytic cocktail for 1448 eclamptic 
patients. 
There was 2.2% Maternal Mortality Rate. 
Side Effects were maternal and fetal respiratory depression. 
Antidote used was Naloxone. 
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DIAZEPAM (LEAN REGIMEN) 
This includes Intravenous administration of 10mg diazepam over 
2mts followed by IV infusion of 40 mg in 500 ml NS for 24 hours. Thus by 
this diazepam infusion the patient is made sedated but arousable. 
Maximum dose is 100 mg in 24 hours. 
 The side effect of diazepam is respiratory depression in mother and 
lethargy and apnoea of new born.Babies had intractable hypothermia  and 
were floppy. 
 No antidote was available, 
 The maternal mortality was 5% in this regimen. 
In 1990 Crowther compared the use of diazepam and MgSO4. It was 
concluded that Recurrent eclampsia occurred in 7% in Diazepam  treated 
patients. Whereas it was 5 % with MgSO4 treated patients. 
In Collaborative Eclampsia Trial, thrice the number of cases had 
recurrent fits when compared to MgSO4. The relative risk was 0.33. In 2006 
Royal College of Obstetricians and Gynaecologists restricted  the use of  
Midazolam  or  Lorazepam  to single dose. This is due to  increased 
maternal  mortality rate. 
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PHENYTOIN : 
Blitz first prepared phenytoin. It was used as an anti convulsant drug in 
1938.  
 
Parenteral :  
Dosage of phenytoin is 10mg/kg by slow IV bolus followed by          
5mg / kg  2  hrs later.  
 
Oral :  
It is followed by oral dosage of 200mg twice daily for 48 hrs after 
delivery. Phenytoin is non sedative. The therapeutic serum levels of 
phenytoin is 40 to 100 micro mol /litre. 
 
Adverse effects are  
 Hypotension 
 Cardiac arrhythmias 
 Thrombophlebitis   in the site of injection. 
A comparative study involving phenytoin and MgSO4 was studied in 
Lalla Ded Medical College at Srinagar ,Kashmir was conducted in the years  
2004 to 2006.It was concluded that 24% recurrent eclamptic seizures were 
there. Such patients were switched over to MgSO4. And no seizure recurred 
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thereafter. Thus MgSO4 is an ideal anticonvulsant drug in the control of 
eclamptic seizures. 
 
Sawney et al reported recurrence of seizure in 40 % cases with 
phenytoin  and it was only  8%  with MgSO4 in a group of 25 patients. Also 
Phenytoin was studied for the prophylaxis of eclampsia in patients with 
severe preeclampsia  by Lucas in the year 1995 .In that 0.9% had eclampsia 
with phenytoin. There was no seizure in patients with MgSO4.  
 
In Collaborative Eclampsia Trial  conducted in 1995 the recurrence of 
seizure was twice in phenytoin group when compared to MgSO4.  The 
maternal mortality was also twice that of  the patients treated with 
MgSO4.The relative risk was 0.5. 
 
MAGNESIUM SULPHATE 
The various Magnesium sulphate regimens were 
1. Pritchard Regimen 
2.Zuspan Regimen 
3.Sibai Regimen 
4.Padhar Regimen 
5.Dhaka Regime 
6.Sokkotto Regimen 
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In Parkland hospital in the year 1955, Pritchard started MgSO4 
treatment regimen which consist both IV & IM of MgSO4 
 
PRITCHARD REGIMEN  
LOADING   DOSE 
Initially as soon as the patient is received after the eclamptic fits she 
is given intravenous  administration of  4 gm of  20% MgSO4  at a rate  not  
exceeding  1g/mt .  And Intramuscular administration of 5 gm of 50% 
MgSo4  in each buttock as deep Intra muscular injection. 
 
MAINTENANCE DOSE 
5 gram of 50% MgSO4  is given as deep intramuscular injection on 
alternate buttocks every 4 hours. MgSO4 continued as IM  maintenance dose 
for 24 hours after delivery (or) 24 hrs after the last fit whichever is later. 
 The injection is given with a 3 inch long, 20 gauge needle. 
If there is recurrence of convulsion within 15 mts,  2gm of 20% 
MgSO4 is given slow intravenously at a rate not exceeding  1gm /minute. 
 
 The following parameters are noted every 4 hours. 
1. Knee jerk should be present  
2. Respiratory rate should be more than 16/mt  
3. Urine output should be atleast 30ml / hr 
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Pritchard’s regimen  though widely used,  He suggested that women 
with low BMI should be given low dose MgSO4. 
 
In  (1962) Flower29  et al adjusted doses according to body weight. In 
2003 Sardesai30 suman et al    studied   low dose MgSO4 in Indian women. 
He reported 90% control of eclampsia and safety  and efficacy of low dose 
MgSO4 inferred. In Dhaka regimen there was 98% control of eclampsia. 
 
ZUSPAN REGIME ( 1964) 
Loading dose: 
  Administration of  4gm of 20% MgSO4 by an infusion pump  over 5 
to 10 minutes. 
 
Maintenance dose: 
This is followed by 20% MgSO4 at the rate of  1-2gm/hour by 
controlled infusion pump for 24 hrs after the delivery of fetus. 
 
PADHAR  REGIME31    
Loading dose : 
IV administration of 6 gm of  50% MgSO4  
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Maintenance dose:  
IM administration of  4 gm of 20% MgSO4. 
 It was a Prospective study conducted in Padhar hospital, India. 95 
eclampsia cases were studied.The result was that only one woman had 
recurrent fits. She was  given 5 gm as IM maintenance. 
 
SOKOTTO  REGIME32 
(Ultra Short)  
Dose  :    
IV administration of  4 grams of  20% MgSO4  and intramuscular 
administration of   10 gms of  50%  MgSO4. 
  At  Sokkotto, capital city of Nigeria, a study was conducted in the 
year july 2007 to june 2008 to study the efficacy  of the ultra short regimen 
in antepartum, intrapartum, postpartum eclamptic patients . 
 There was 7.4% of recurrent seizures within 4 hours  of loading dose 
in this study. Out of 121 patients, 12 mothers died. Thus case fatality rate 
was 9.9% in that study. Thus it was concluded that the efficacy of Sokkoto’s 
regimen was 92.6% in that study.   
 
SIBAI  REGIME33 
Loading dose: 
IV administration of 6 gm of 20% MgSO4    
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Maintenance  dose: 
  IV infusion of  20% MgSO4  for 24 hours after the fit. 
 
DHAKA  REGIME (1998) : 
Loading  dose :  
4 gm of 20% MgSO4  IV at a rate not exceeding  1 gm per minute. IM  
6 gm of 50% MgSO4 as deep IM, 3gm in each buttock. 
Maintenance dose: 
2.5gm of  50% MgSo4  IM  on alternate buttock every 4 hours. This  
prospective study was done in in Dhaka Medical college hospital in March 
to June 1998.Out of 65 eclamptic patients only one developed recurrent fits 
that occurred 3 hours after the loading dose. It was treated with diazepam 
and intramuscular maintenance dose. It was concluded that half the dose 
will be enough to control the fits.  
 
MAGNESIUM SULPHATE   
 The chemical formula of MgSO4  is  MgSO4. 7H2O . 
 It is also called as Epsom salt. 
 1 gm of MgSO4 has 98mg of elemental Magnesium. 
 The molecular weight of MgSO4 is 24.3. 
 Ph is 6.0.(5.5 to 7.0) . 
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 The  Osmolarity of 50% MgSO4  is 4.06 mosm/ml. 
 It should be stored in room temperature. (15 to 30 deg C) 
Horn first used MgSO4 intrathecally to avoid eclamptic fits 
prophylactically in the year 1906.   
 
PLASMA LEVELS AND DISTRIBUTION  
40% of plasma magnesium  is protein bound after administration. The 
remaining 60% of magnesium diffuse into extravascular compartment like 
the extracellular space. It  crosses  the placenta, into the fetus and liquor.  
The volume of distribution  reaches constant  levels in the 4th hour after 
administration. There are 2 phases in the pharmacokinetic  profile of 
MgSO4. They are Rapid  Distribution phase and Slow phase of Elimination. 
 
EXCRETION 
Magnesium sulphate  which is given in    is cleared by renal excretion 
only. 50% of the dose is excreted after 4 hours and 90% of the total dose is 
excreted  with in a  period of 24 hrs.  Glomerular filtration rate  can  be 
evaluated by the estimation of  serum creatinine. 
 
MECHANISM  OF ACTION: 
 Mechanism of action of MgSO4 which are proposed  are  
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CENTRAL ACTION: 
 Decreases the pre synaptic release of neurotransmitter Glutamate,an 
excitatory neurotransmitter. 
 Blocks the Glutaminergic N- methyl D–aspartate  NMDA receptors in 
Hippocampus which has a low seizure threshold. 
 
PERIPHERAL ACTION:  
 Adenosine action is potentiated  
 Improves the calcium   buffering  action in mitochondria. 
 Blocks the calcium entry through  voltage gated channels.It was 
reported by  Arango34 and mejaMantilla in 2006 . 
Thus MgSo4  has a central anticonvulsant action as well as peripheral  
action on neuro muscular junction. 
 MgSo4 is a potent  vasodilator in  mainly cerebro vasculature. 
Therefore  it  reverses   the vaso constriction which is the main cause 
for preeclampsia and  thereby  eclampsia. 
 
 In 1986  Cotton35 and Colleagues found that there is a  fall in 
Mean Arterial Pressure and 13% rise in cardiac index . 
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Other effects of MgSO4 
1. Vascular effects: 
Vasodilator in vascular beds resulting in Flushing,Head ache 
2. Uterine effects : 
Transient decrease in the myometrial activity immediately during and  
after the loading dose. Hence it is used in preterm labor. 
      
FETAL EFFECTS OF MgSO4  
Neonatal  depression  is directly related to hypermagnesemia. It also 
affects fetal heart rate especially beat to beat variability. Hence  biophysical 
profile is not  useful at  time of MgSO4 adminstration.It is also reported that 
MgSO4 prevents the neonates from  developing  cerebral  palsy. 
 Nelson36 and Grether (1995) conducted randomized trials and 
assessed the neuro protctive effects. 
        Doyle37 and associates (2009) conducted five randomised trials 
including 6145 infants and concluded that gross motor dysfunction was 
reduced in  the babies of mothers treated with MgSO4. 
 
SERUM  MAGNESIUM  LEVEL  
 Normal serum  mg level is  1-2 meq/L  
 Therapeutic  level  of serum magnesium:- 
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Usually eclamptic fits are controlled when the plasma magnesium level is 4 
to 7 meq/L 
 
ADVANTAGES OF MgSO4  
Magnesium Sulphate  is 
 very efficient    
 fastly acting 
 wide safety  margin  
 not toxic to fetus and mother  
 easy for administration and for monitoring    
 effective antidote 
 low cost 
 cause less sedation. 
 
TOXIC EFFECTS OF MAGNESIUM   AND MONITORING OF 
SERUM MAGNESIUM 
 When serum Mg level is  9-10 meq/L  the patellar reflex 
becomes  absent. The MgSO4 regime is withheld. Serum 
Magnesium  can be  estimated  if there is loss of patellar reflex, 
but it is very rarely needed since there is a wider margin of 
safety. 
            
 32 
Duley at al38 (1995) showed that there is no need to measure  the 
Serum Magnesium level. Serum magnesium  measurement  is used only for 
the patients who develop magnesium  toxicity symptoms.It is also measured 
when serum creatinine is more than 1 mg/dl  
 When serum Mg level reaches above10meq/L respiration becomes 
weakened due to curare effect. 
 When Mg level in plasma reaches  above 12 meq/L respiratory 
paralysis and  respiratory arrest follow. 
There is no adverse effect on cardiac function. 
 
Antidote: 
1g of 10% Calcium gluconate or calcium chloride intravenously   
over 15  minutes. Along with this   magnesium sulphate is stopped to 
reverse the toxic effect of respiratory depression.  
For severe  respiratory depression  or  respiratory  arrest mechanical 
ventilatory  support becomes necessary. 
 
MgSO4 IN RENAL FAILURE: 
 
 Even if the patient already has renal failure, the loading dose of 
Magnesium Sulphate  can be safely given. This is because after distribution 
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of Magnesium, a loading  dose of MgSO4 achieves the desired therapeutic 
level and the maintenance  dose (infusion dose) maintains the steady level. 
Thus only maintenance dose should be reduced in cases of renal failure. 
 
American39 College of Obstetricians and Gynecologists (2002) a ; 
Royal College40 of Obstetricians and Gynecologists(2006) has 
recommended that  it is not needed to measure  the plasma magnesium level 
in all cases routinely.    
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DRUG INTERACTIONS  WITH MAGNESIUM SULPHATE 
 
Agent Effect of MgSO4 Recommendations 
Neuromuscular  
blocking  agents- 
depolarising & non 
depolarizing 
(succinyl  choline) 
Activity is increased 
Dosage of neuro 
muscular blockers 
should  be  reduced. 
Depressant  drugs of 
central nervous system. 
General anaesthetics- 
opioids, barbiturates 
Additive effect of CNS 
depression 
Needs reduction of dose 
of the CNS depressant 
drugs 
Nifedepine Hypotension 
Concurrent 
administration can be 
avoided 
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ANTI HYPERTENSIVE DRUGS 
CLASS DRUG 
AVAILA 
BILITY 
FORM 
STAR 
TING 
DOSE 
MAXI
MUM 
DOSE 
SIDE EFFECTS 
     
 
Adrenargic  
blockers Labetolol 50,100mg 100mg TDS 
2400 
mg Edema, Fatigue 
Alpha 
Blocker Prazosin 1mg 1mg BD 20mg 
Drowsiness 
Dizziness 
Centrally 
Acting 
 Alpha  
    methyl dopa  
 
250mg 
 
 
 
TDS 
 
 
 
2g 
 
 
 
Postural 
hypotension 
drowsiness 
depression dry 
mouth, 
 
Calcium  
Channel 
blockers 
Nifedepine 5mg 10 mg 
10mg  
TDS 120mg 
Headache 
fatigue 
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HYDRALAZINE: 
       It is an arterial vasodilator 
American College of Obstetricians and Gynaecologists ( 2002) has 
recommended the following dose. 
            DOSE   :Initially 5 mg  IV .It is repeated at interval of 15 to 20 
minutes as 5 or 10 mg  till the diastolic BP becomes 90 to100 mmHg.                   
A maximum of 5   IV doses can be repeated . 
Onset of action  can be as rapid as 10 minutes. BP thus lowered saves 
the patient from developing Intra cerebral haemorrhage. 
If the dose is given more than recommended ,it results  in decreased   
utero placental perfusion leading to fetal heart rate decelerations. 
Side effects are  palpitation, tachycardia. 
 
LABETOLOL:  
It is an α and  blocker. The National High  BP Education 
Programme  working group ( 2000) and American College of Obstetricians 
and Gynaecologists in (2002 )recommended the following dose. 
 20 mg  IV bolus.    
If it did not decrease the BP within 10 minutes, the dose can be 
doubled every ten minutes upto a maximum of 220 mg dose per episode . 
Oral dose : 50 mg BD 
Side effects  are  hypotension,  bradycardia.  
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Vigil De Gracia41 and associates  ( 2007)  reported that there was no 
difference in maternal and perinatal outcome  in   between patients treated 
with Hydralazine and Labetolol. 
 
NIFEDIPINE : 
It is a   dihydropyridine derivative-- Calcium Channel Blocker 
Dose recommended by National High BP Education programme and          
Royal College of Obstetricians and Gynaecologists in 2006 is 
Initially 10 mg orally  and it is repeated every 30 minutes.maximum 
dose is 200mg. 
Side effect: 
               head ache 
               ankle edema 
               flushing 
               palpitation 
               hypotension 
                        tachycardia 
 
ROLE OF DIURETICS: 
 Diuretics causes intravascular volume depletion and thereby 
decreases utero placental blood flow. Hence Zeeman42 (2009) has 
recommended  the limited  usage of  diuretics only in  pulmonary edema.    
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 OBSTETRICAL  MANAGEMENT OF ECLAMPSIA     
Royal College of Obstetricians and Gynecologists  Guidelines (2005)  
says that  Termination of pregnancy is the definitive treatment of eclampsia.  
 
 The mode of  Delivery  should be   vaginal in order to avoid maternal 
risk due to caesarean section. Per vaginal  examination is done to assess  the 
Bishop score of cervix and if the cervix is favorable, induction of labour is 
done using prostaglandin (PGE2) gel (or) augmentation of labour done using 
oxytocin administration. Thus PGE 2 and  Oxytocin  are used for the 
successful    vaginal  delivery. Blood pressure  should monitored and anti 
hypertensive drug should be used whenever necessary throughout labour 
and after labour too.  
 
 Alanis & associates43(2008) reported that labour ensues 
spontaneously following an eclamptic fit, or can be  successful  even if the 
pregnancy is remote from term. This is because in antepartum eclampsia the 
uterine contractions will increase in frequency and intensity. If the seizure 
delivery interval is more, when waiting for vaginal delivery there may be 
serious morbidity in the  postpartum period for the patient. Hence the 
seizure to delivery interval has a significant role.  
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The caesarean section (or) hysterotomy is done in the following 
situations: 
1. Obstetric  Indication 
2. Unfavorable  cervix  so that vaginal delivery is impossible  within 6 
to 8 hours of occurrence of first episode of eclamptic fits. 
3. All deeply unconscious patients and if the delivery is not imminent.  
4. All uncooperative patients due to postictal confusional state 
5. Fetal distress 
 
MANAGEMENT OF LABOUR 
The first stage of labor is monitored for uterine contractions. 
Partograph maintained. I/O Chart maintained.      
The second stage of labour should be cut short and elective forceps 
delivery can be used.  
The third stage of labour should be treated actively to prevent Post 
Partum Haemorrhage. Since the eclamptic patients have decreased blood 
volume when compared to normal pregnant  these patients cannot withstand 
postpartum haemorrhage.  
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So PPH is prevented by 
1. Inj. oxytocin 10 units IM  after the delivery of anterior shoulder     
(or) 
2. Inj.Prostaglandin   PGF2α  250μg as intramuscular injection  (or) 
3. Tab.Misoprostol( PGE1 analogue) 600 to 800μg kept per 
rectally.   
Methyl erogometrine is contraindicated   since it causes increase in 
blood pressure. 
 Blood transfusion is given for the required cases. 
 
POST PARTUM CARE: 
After the delivery of  baby  blood pressure, urine output, general 
condition of the patient  should  be monitored  continuously for a period of 
48hrs of delivery.Limitation of IV fluids 75 ml/hr was done because of the 
high hemoconcenteration.   
 
In recent years, in developed countries due to intensive prenatal care, 
ante partum eclampsia is reduced and the incidence is more in postpartum 
eclampsia.  
 
Chames44 & colleagues ( 2002)  showed   that  an incidence  of  20% 
of the total elcampsia cases can be postpartum and hence the postnatal  
            
 41 
period should be carefully monitored. Anti hypertensive  drugs can be 
tapered off gradually as the blood pressure is controlled .  
 
 First sign in the postpartum period to get well is the better urine 
output. 
 Edema disappears after one week after of delivery. 
 BP  takes two weeks to become normal 
 Proteinuria disappears after one week. 
  
Reversible cerebral vasoconstriction syndrome 
Some patients continues to have high BP, recurrent fits, neurological 
sequalae. It is seen in patients with severe vasospasm which causes ischemic 
and  infarct areas in brain.  
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MATERIALS AND METHODS 
 
 This study was conducted at Raja Mirasudhar  Hospital, Thanjavur in 
the Department of Obstetrics & Gynaecology  during the period of  January 
2011 to  January 2012  and  100 eclampsia patients including antepartum 
eclampsia, intrapartum eclampsia, post partum eclampsia were included for 
the purpose of this study.  Magnesium Sulphate  was used for the  
management of  eclampsia. 50 eclamptic  patients were treated with 
Pritchard regimen and other 50 with Dhaka regimen. 
 
INCLUSION CRITERIA 
All  eclamptic  woman   antepartum, intrapartum, postpartum patients 
were included in the study irrespective of their age, gestational age, parity 
and status of booking.  
 
EXCLUSION CRITERIA 
 Patients who have already received Magnesium sulphate outside. 
 Patients with known epilepsy  
 Patients  with known  Heart Block, Renal Failure 
 Onset of seizures more than 72 hrs after delivery in post partum  
eclampsia cases 
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Totally about 134 eclampsia cases were admitted in the period 
between January 2011 to 2012. Of which 34 patients were excluded 
according to exclusion criteria. 
 
STUDY DESIGN 
Randomized  control  Trial .  
 
GROUP P:  
Treatment of  50 patients  randomly with Pritchard’s regimen of 
Magnesium Sulphate. 
 
GROUP D: 
Treatment of 50 patients randomly with Dhaka regimen of 
Magnesium Sulphate. 
 
HISTORY  
History was elicited from the patient and her attendants  if she was 
brought in a postictal state or unconscious state. Then the history was 
confirmed when the patient regained her consciousness. History regarding 
her age, parity, booking  status, gestational age, number of eclamptic fits 
before admitting here, whether she was a known  case of pregnancy 
induced hypertension, whether she is on anti hypertensive drugs, presence 
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of edema if so  how long, existence of  imminent symptoms like head ache, 
vomiting, blurring of vision  were all elicited thoroughly.  BMI was 
calculated  from  her old records. Any known history of Epilepsy, Renal 
failure, Heart block were also elicited in a detailed manner. 
 
CLINICAL EXAMINATION  
  General examination of the patient from head to foot was made.  
If the patient was admitted in a state of throwing fits suction of  air 
way done.And airway  maintained .IV line started and MgSO4 administered 
according to the regimen. During this time bed side rails are elevated. A 
soft padded mouth gag is inserted in between teeth to prevent gag reflux. 
On General examination, the following were noted. 
 the  state of consciousness of the patient , 
 the presence of anaemia 
 degree of pedal edema, 
 presence of facial edema,edema  in hands  
 Pulse Rate, Blood  Pressure, Temperature, Respiratory Rate all were 
measured. 
 Cardiovascular system, Respiratory system were examined 
thoroughly. 
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 IV line was started  and blood samples  sent for Renal Function Test, 
Liver Function Test, Prothrombin time, Complete blood count .  
 Fundus examination was done by ophthalmologist 
 The patient was catheterized  with foley’s indwelling  catheter and 
urine output  noticed immediately and monitored  every hour. Urine 
sample was sent for estimation of proteinuria 
 Continuous monitoring of oxygen saturation, pulse rate , Blood 
pressure were recorded.  
 Knee jerk, Respiratory rate were noticed every 4 hours . 
 
OBSTETRIC   EXAMINATION 
Per abdomen examination of the uterine fundus height, presence of 
contractions noted.viability of the fetus assured by fetal heart rate. 
Per vaginal examination done under strict aseptic precautions. 
favourabilty of the cevix assessed by Bishop score. 
 
MANAGEMENT  OF ECLAMPTIC  FITS: 
STUDY GROUP: 
          DHAKA REGIMEN: 
CONTROL GROUP: 
          PRITCHARD  REGIMEN 
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Here patients  were randomly selected and  treated in both Regimens. 
 
 
MANAGEMENT OF BLOOD PRESSURE WITH ANTI HYPERTENSIVE 
DRUGS  
Hypertension is treated with antihypertensive drugs like                
Tab.Nifedepine 10mg  and IV Labetolol. 
 
OBSTETRIC MANAGEMENT:- 
A detailed obstetric examination  was  made .Mode  of  delivery  was 
decided according to the Bishop scoring ,Gestational                                    
age  and the viability of fetus. 
Labour  was induced with prostaglandin  PGE2 gel. The patients who 
came in active phase of labour were accelerated with amniotomy if 
membranes present and oxytocin infusion.If membranes absent oxytocin 
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infusion initiated. During labor uterine contractions and FHR 
monitored.partograph maintained. 
  Ceasarean section (or) Hysterotomy was performed in patients with 
unfavorable cervix, obstetric  indication and for failed induction. 
Perinatal outcome was also observed with the APGAR score.birth 
weight noted.The babies were followed up till the day of discharge. 
After the delivery, the eclampsia  patients were watched 
vigilantly,MgSO4 continued till 24 hours after the delivery of fetus or 24 
hours after the last fit.  Only when they were stabilised, they  were shifted  
to post operative ward or post natal ward and observed there and the patients 
were followed up till the  date of discharge. On the time of discharge she 
was advised to review in postnatal OP even if she maintained normal BP . 
Counselling regarding future pregnancy was given . Regular antenatal visits 
were insisted to diagnose pre eclampsia at an early stage for low dose 
aspirin. This is because recurrent preeclampsia is 3.4% in subsequent 
pregnancy and recurrent gestational hypertension is 25%.  
Postnatally patients were monitored BP and treated with Tab. 
Atenolol, Tab.Nifedepine, Tab. Enalapril. 
  
 
 
OUTCOME MEASURES: 
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Recurrence of fits was considered as the primary outcome measure  
after  starting  the patients  on both  Magnesium sulphate   regime. The 
outcome  of mother as maternal morbidity  and mortality were compared. 
Perinatal  outcome  were also compared in both regimens.  
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RESULTS AND ANALYSIS 
TABLE : 1 
DISTRIBUTION OF AGE 
 
Dhaka regime Pritchard regime 
Age Group 
(n=50) (100%) (n=50) (100%) 
Below 20yrs 12 24.0% 13 26.0% 
21 to 25yrs 24 48.0% 23 46.0% 
26 to 30yrs 9 18.0% 14 28.0% 
31yrs & above 5 10.0% 0 0% 
Total 50 100.00% 50 100.00% 
Mean 23.80 23.26 
 
In the present study 25 patients were below 20 years.Between 21 to 
25 years there were 47 patients.23 patients were between 26 to 30 years.The 
mean age  of the patients in Dhaka regimen was 23.8 .The mean age in 
Pritchard patients was 23.26. In both Dhaka and Pritchard regime , the age 
of the patients does not differ significantly. 
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TABLE : 2 
DISTRIBUTION OF PARITY 
 
Dhaka regime Pritchard regime 
        Parity 
(n=50) (100%) (n=50) (100%) 
Primi 30 60.0% 31 62.0% 
Multi 20 40.0% 19 38.0% 
Total 50 100.00% 50 100.00% 
 
Total primi in the present study is 61.  
31 primi  (62%)  and 19 multi (38%)were treated under Pritchard 
regimen. Under Dhaka regimen 30 primi (60%) and 20 multi (40%)were  
treated.  
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TABLE : 3 
STATUS OF BOOKING 
Dhaka regime Pritchard regime 
Age Group 
(n=50) (100%) (n=50) (100%) 
Booked 30 60.0% 30 60.0% 
Unbooked 20 40.0% 20 40.0% 
Total 50 100.00% 50 100.00% 
 
Total number of booked patients were 60.30 each in Dhaka and 
Pritchard regime. Unbooked patients were 20 each in both the regimens. 
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FIG. 3 
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TABLE : 4 
GESTATIONAL AGE 
Dhaka regime Pritchard regime Gestational Age 
(weeks)  (n=50) (100%) (n=50) (100%) 
Below 28 6 12.0% 4 8.0% 
28 to 37 26 52.0% 29 58.0% 
More 37 18 36.0% 17 34.0% 
Total  50 100.00% 50 100.00% 
Mean 34.91 35.06 
P Value 0.856 (insignificant) 
 
In the  study group 26 patients were between 28 to 37 weeks.18 were 
more than 37weeks.6 patients were below 28 weeks. 
In the Pritchard group 29 patients were between 28 to 37 weeks.           
17 patients were more than 37 weeks.4 were below 28 weeks. 
The mean  gestational age for Dhaka regimen group is 34.91 weeks. 
The mean age for Pritchard regimen was 35.06 weeks.                                         
The p value is 0. 856. 
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TABLE : 5 
DISTRIBUTION OF BODY MASS INDEX 
Dhaka regime Pritchard regime 
BMI 
(n=50) (100%) (n=50) (100%) 
Low ( <19.8) 5 10.0% 0 0% 
Normal (19.8 to 26) 41 82.0% 45 90.0% 
High (26 to 29) 3 6% 4 8.0% 
Obese ( >29) 1 2% 1 2.0% 
Total  50 100.00% 50 100.00% 
 
In Dhaka regimen group, 41 patients were with normal BMI.5 
patients were with low BMI.  In Pritchard regimen group 1 obese, 4 with 
high BMI and 45 with normal BMI were treated.   The p value is 0.03. 
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FIG : 5 
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TABLE : 6 
STATE OF CONSCIOUSNESS 
 
Dhaka regime Pritchard regime STATE OF 
CONSCIOUSNESS (n=50) (100%) (n=50) (100%) 
Conscious 44 88.0% 44 88.0% 
Post ictal confusion 4 8.0% 4 8.0% 
Un consious 2 4.0% 2 4.0% 
Total  50 100.00% 50 100.00% 
 
In patients treated under  Pritchard regimen 44 were admitted in 
conscious state.4 were in post ictal confusion and 2 were brought in an 
unconscious state. In patients treated under Dhaka regimen 44 were 
conscious,4 were in postictal confusional state and 2 were unconscious.  
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FIG : 6 
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TABLE : 7 
TYPES OF ECLAMPSIA 
Dhaka regime Pritchard regime TYPES OF 
ECLAMPSIA (n=50) (100%) (n=50) (100%) 
Antepartum 40 80.0% 43 86.0% 
Intrapartum 4 8.0% 1 2.0% 
Postpartum 6 12.0% 6 12.0% 
Total 50 100.00% 50 100.00% 
 
 Among the 83 antepartum eclampsia patients, 40  were treated under 
Dhaka regimen. 43 patients were treated under Pritchard regimen. 6 
postpartum eclampsia patients were treated under Dhaka regimen as well as  
under Pritchard regimen. 1 intrapartum eclampsia patient was treated with 
Pritchard regimen. 4intrapartum  eclampsia cases were treated under Dhaka 
regimen.  
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TABLE : 8 
SYSTOLIC BLOOD PRESSURE 
 
Dhaka regime Pritchard regime SYSTOLIC BLOOD 
PRESSURE (n=50) (100%) (n=50) (100%) 
Below 120 2 4.0% 4 8.0% 
121 to 140 14 28.0% 9 18.0% 
141 to 160 6 12.0% 15 30.0% 
161 & above 28 56.0% 22 44.0% 
Total 50 100.00% 50 100.00% 
Mean 154.56 149.60 
 
In Dhaka regimen 28 patients had  systolic BP above 161mmHg ,16 
patients had below 140 mmHg . Among them 2 were below 120 mmHg. 
The mean systolic BP was 154.56mmHg in patients treated under Dhaka 
regimen.   In patients treated under Pritchard 22 had systolic BP above 161 
mmHg. 13 were below 140  mmHg. Within that 4 had BP below 120 mmHg 
. The mean systolic BP was149.60 mmHg. The p value is 0.681 and it is 
insignificant. Thus 12% had BP even below 120 mmHg. 
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TABLE :9 
DIASTOLIC BLOOD PRESSURE 
 
Dhaka regime Pritchard regime DIASTOLIC BLOOD 
PRESSURE (n=50) (100%) (n=50) (100%) 
Below 90 3 6.0% 6 12.0% 
90 - 99 11 22.0% 9 18.0% 
100 - 109 18 36.0% 16 32.0% 
110 & more 18 36.0% 19 38.0% 
Total 50 100.00% 50 100.00% 
Mean 100.00 98.80 
 
18 Patients  under Dhaka regimen had more than 110 mmHg diastolic 
BP. Another 18 had diastolic BP in the range of 100 -109 mmHg.11 had 
diastolic BP in the range  of 90 -99 mmHg.3 patients had diastolic BP below 
90 mmHg. The mean value is 100mmHg. 
In Pritchard regime 19 patients had  diastolic BP more than 110 
mmHg.16 patients had 100-109 mmHg. 9 had 90-99 mmHg.6 had normal 
BP. The mean value is 98.8 mmHg. 
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FIG : 9 
DIASTOLIC BLOOD PRESSURE 
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TABLE : 10 
MODE OF DELIVERY 
 
Dhaka regime Pritchard regime 
MODE OF DELIVERY 
(n=50) (100%) (n=50) (100%) 
 LSCS / Hysterotomy 26 52.0% 26 52.0% 
    Labour natural 17 34.0% 20 40.0% 
Outlet forceps 1 2% 0 0% 
Induced  Abortion 
/spontaneous expulsion 
6 12.0% 4 8% 
Total 50 100.00% 50 100.00% 
 
In patients treated with Dhaka regimen 26 underwent LSCS / 
Hysterotomy.17 delivered  by labour natural. For 1 patient outlet forceps 
applied for fetaldistress. There were 6 induced  abortions/ spontaneous 
expulsion.  In patients treated with Pritchard 26 were underwent  LSCS ,20  
delivered  labor naturally. 
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TABLE : 11 
METHOD OF INDUCTION FOR VAGINAL DELIVERY 
 
Dhaka regime Pritchard regime METHOD OF 
INDUCTION (n=50) (100%) (n=50) (100%) 
PGE2 Gel 8 16.0% 8 16.0% 
             Oxytocin 12 24.0% 11 22.0% 
ARM/Oxytocin 
augmentation 
4 8.0% 5 10.0% 
Total 24 48.00% 24 48.00% 
 
 In this study  48 patients delivered vaginally. In Dhaka regime   8 
patients were induced with PGE2 gel and 12 patients were induced with 
oxytocin. Four patient’s labor were augmented with artificial rupture of 
membrane  followed by oxytocin infusion. In Pritchard regime, PGE2 gel 
and Oxytocin were used for 8 and 11 patients respectively. 
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FIG : 11 
METHOD OF INDUCTION FOR VAGINAL DELIVERY 
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TABLE : 12 
  SEIZURE TO DELIVERY INTERVAL IN AP ECLAMPSIA 
Dhaka regime Pritchard regime  SEIZURE TO 
DELIVERY 
INTERVAL(Hr) 
(n=50) (100%) (n=50) (100%) 
2 21 42.0% 18 36.0% 
2 to 6 20 40.0% 19 38.0% 
More than 6 Hrs 1 2.0% 4 8.0% 
Total  42 84%      41 82.00% 
 
There were 83 antepartum eclampsia cases in this study. 
Out of 42 antepartum eclampsia  patients treated with Dhaka 
regime,21 delivered within 2 hours.20 delivered within 2 to 6 hours. Only                 
1 delivered after 6 hours. 
Out of 41 antepartum eclampsia patients 18 delivered within                         
2 hours. 19 delivered between 2 to 6 hours.4 patients took more than                     
6 hours.  
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TABLE  : 13 
RECURRENCE OF FITS 
 Dhaka regimen 
      Pritchard         
regimen 
Sl. 
No 
Fits 
(n=50) (100%) (n=50) (100%) 
1 Nil 49  98% 49  98% 
2 Recurrence 
of fits 1 2% 1.0 2% 
 
One patient from each regime had recurrence of fits. The patient in 
the Dhaka regime developed another convulsion after 3 hours of loading 
dose. One patient who developed recurrence of fit in Pritchard regime had 
that convulsion  2 hours after loading dose. 
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TABLE : 14 
MATERNAL COMPLICATIONS  
Dhaka regime Pritchard regime 
 
(n=50) (100%) (n=50) (100%) 
 Abruption 2 4.0% 2 4.0% 
             HELLP 1 2.0% 1 2.0% 
           Pulmonary Edema 5 10.0% 2 4.0% 
Cerebro vascular accident 1 2.0% - 0% 
Nil 41 82.0% 45 90.0% 
Total 50 100.00% 50 100.00% 
 
 In Dhaka regimen 2 patients had abruption,1 had HELLP and  5 had 
pulmonary edema.One patient developed occipital lobe infarct. In Pritchard 
regime  2 had abruption. 1 patient had HELLP and  2 had pulmonary edema. 
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FIG : 14 
MATERNAL COMPLICATIONS  
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TABLE  : 15 
MATERNAL OUTCOME 
 
Dhaka regime Pritchard regime 
MATERNAL 
OUTCOME 
(n=50) (100%) (n=50) (100%) 
Alive 49 98.0% 49 98.0% 
               Death 1 2.0% 1 2.0% 
Total    50 100.00% 50 100.00% 
 
In this study, out of the 100 patients, 98 were discharged from the 
hospital without any sequlae. 2 patients died due to complication of 
eclampsia. 
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FIG  : 15 
MATERNAL OUTCOME 
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TABLE  : 16 
BIRTH WEIGHT 
 
Dhaka regime Pritchard regime 
BIRTH WEIGHT 
(n=50) (100%) (n=50) (100%) 
Less 1 kg 6 12.0% 4 8.0% 
1 to 2kg 22 44.0% 29 58.0% 
more than 2kg 22 44.0% 17 34.0% 
Total 50 100.00% 50 100.00% 
 
In Dhaka regimen  the mean birth weight of the babies was 1.9332.           
In Pritchard regimen the mean birth weight of babies was 1.8410.                     
The p value is 0.548 
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TABLE  : 17 
PERINATAL OUTCOME 
 
Dhaka regimen Pritchard regimen 
Sl.no Perinatal outcome (n=50) (100%) (n=50) (100%) 
1 Alive 40 80.0% 37 74.0% 
3 Perinatal death 10 20.0% 13 26% 
 
In patients treated under Dhaka regimen 40 babies born alive. 10 died 
perinatally. In patients treated under Pritchard regimen 37 babies were alive 
and 13 died perinatally.   
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FIG   : 17 
PERINATAL OUTCOME 
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TABLE  : 18 
CAUSE OF PERINATAL DEATH 
 
Dhaka regimen Pritchard regimen 
Sl.no 
Cause of 
perinatal 
death (n=50) (100%) (n=50) (100%) 
1 
Low birth 
weight 
5 10.0% 4 8.0% 
2 Prematurity 3 6.0% 6 12% 
3 Asphyxia 2 4.0% 3 6% 
 
Among the 10 perinatal death in Dhaka regime patients, Low birth 
weight (10%), Pre maturity (6%) and Asphyxia (4%) were the cause of 
perinatal mortality. In Pritchard  regime the above said causes contributed to 
8%,12% and 6% respectively. 
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FIG   : 18 
CAUSE OF PERINATAL DEATH 
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DISCUSSION 
 
 The Maternal Morbidity is  very much decreased with the control of 
eclamptic fits. MgSO4 is an anticonvulsant drug used in the treatment of 
Antepartuum, intrapartum, postpartum  eclampsia which has a wider margin 
of safety and rapid onset of action. Although rare the toxicity symptoms of 
magnesium toxicity can be corrected by antidote calcium gluconate which is 
readily available.  Magnesium sulphate act as an ideal anti convulsant drug  
in the control of eclamptic  fits. The Collaborative Eclampsia Trial has 
provided ample evidence that compared with  other anti convulsants like 
Diazepam, phenytoin. Also the additional doses of MgSO4 in the form of 
maintenance dose is not  associated with any side effects to mother and her 
fetus.  
 
Magnetic resonance angiographic imaging & computed tomographic 
scan has proved that vasospasm in the blood vessels of brain and thereby  
ischemia, which is the basic pathogenic mechanism responsible for the 
eclampsia and it   is reversed by MgSO4. Magnesium exhibit an inhibitory 
action on the cortical discharge from brain and oppose the glutamate N- 
methyl D- aspartate receptor, an excitatory receptor. 
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MgSO4 adminsitrated also inhibit acetyl choline release at motor end 
plate level This is because of hypocalcemia caused by mgso4 (Argany45 and 
mejia –Mantilla, 2006)33 
 
In this present study loading dose of MgSO4 totally 10gms and                 
maintenance dose of 2.5 gm MgSO4  4 hourly given as Intra muscular 
injection  is given. It is  just over half  the dose of pritchard regimen.  
 
AGE DISTRIBUTION:  
 
 In this present study, 47% of patients were in the age group of 21-25 
yrs and  for 25% the age was below 20. In 1989, a study conducted in 
N.W.M. hospital, Bombay reported that 56.8% were between 21-29 years, 
40.5% were under 20 years and 2.7% were above 30 years. This present 
study is comparable to Lolkand et al (1997) study which reported that 
40.7% eclamptic patients were under 20 years. 
In this present study, the mean age of the patients studied under  
Dhaka regimen  was   23.8 years  and the mean age in Pritchard  regimen 
was –23.26 years.  Katz et al46 (2000)study  in sacred Heart Medical Center,   
the mean age of all eclampsia cases was 22 years. 
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 PARITY DISTRIBUTION:  
In this present study, among the 100 patients, 61% of               
patients were primi and 39% were multi. There were 64.9% primi and 
35.1% were multi  in a study conducted at N.W.H Hospital, Bombay.(1989) 
In  Collaborative  Eclampsia  Trial47  (1995)  primi  were  64% and multi 
were 36%. In both  these studies, parity distribution is comparable to the 
present study. 
 
GESTATIONAL AGE 
In this study, in Dhaka regimen, the mean gestational age was –34.91 
weeks and in Pritchard regimen the mean gestational age was35.06 weeks. 
35% of the patients gestational age was more than 37 weeks. Of these 
patients 18%  were treated under Dhaka regime and 17% were treated under 
Pritchard regime. In this present study 65% of patients had gestational age 
less than 37 weeks . In Collaborative  Eclampsia  Trial Group (1995) study, 
gestational age  less than 34 weeks was 39.5%  and gestational age between 
34-36 weeks were 25.5% .Thirty three percent (33%) cases were at term  
gestation. Gestational age of the patients in the present study is comparable 
with collaborative eclampsia trial. 
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DIASTOLIC  BLOOD PRESSURE   
In this present study, the diastolic blood pressure range was 90- 110 
and above. 54% patients who developed eclampsia had diastolic blood 
pressure between 90-110 mmHg. 37% of patients had severe preeclampsia 
with the diastolic blood pressure above 110 mmHg. And 9 % of the patients 
were normotensive. In  Collaborative  Eclampsia Trial  group study (1995), 
patients with  diastolic BP of  more than 110 mm Hg  were 53% . 
 
RECURRENCE  OF  ECLAMPLSIA  
In this study, the recurrence of eclamptic fits was 2 % .Reccurence of 
convulsions occurred both in Dhaka regime (one patient) and Pritchard 
regime (one patient). Collaborative Eclampsia Trial Group (1995) 
extensively studied 1687 women with eclampsia, They compared the 
efficacy of MgSO4 with other anti convulsants namely Diazepam and 
Phenytoin. They showed 9.7% recurrence of seizures in the MgSO4 regime. 
 
Begum et al (1998) studied 65 eclamptic patients with Low dose  
MgSO4 ( Dhaka regime ). 1.5% of patients had recurrent convulsions. 
Bangal48 et al (2009) studied 50 patients with eclampsia and who were 
treated with 4g of 20% MgSO4 intravenously followed by 2gm of 50% 
MgSO4 intramuscular  every 4 hours and reported 6% recurrence of fits.And 
they shifted to Pritchard regime for these patients. 
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Bissallah37 A Ekele et al (2009) studied 121 patients  with eclampsia 
and treated with Ultra short regime ( Sokotto regime ). In ultra short regime 
loading dose of  4g of 20% MgSO4 intravenously followed by 10gm of 50% 
MgSO4 intramuscularly given. No maintenance dose was given for those 
patients. 7.4 % of patients developed recurrence seizures. 
 
MODE OF DELIVERY 
In this present study, under Dhaka regime 26 patients (52%) were 
delivered by Caesarean section/ hysterotomy. Remaining 24 patients (48%) 
delivered vaginally. 26 patients (52%) under Pritchard regime were 
delivered by Caesarean section. 24 patients (48%) delivered vaginally. 
This observation in the mode of delivery is in contrast with Alexander  
and colleagues (1999)who  induced labor  in  50% cases. 15% patients 
responded and delivered vaginally. 35% of patients underwent caesarean 
section because of failed induction. 
 
MATERNAL  MORTALITY 
 In this present study, 2 patients (2%) died due to complication of 
eclampsia. One patient in Dhaka regime died of  intra cranial  haemorrhage. 
Since the patient’s general condition was not conducive for mobilizing the  
patient, CT scan was not done. One patient in Pritchard regime died of 
pulmonary edema. 
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 The patient admitted with the history of convulsion  and admitted in 
a state of unconsciousness with pulmonary edema. 
 In Collaborative Eclampsia Trial ,the maternal mortality was 3.8% 
when treated with Magnesium sulphate. Bissallah A Ekele et al (2009) 
reported 12 maternal deaths in 121 patients (9.9%). 
Shika sheth et al (2010)49 studied 66 eclampsia patients and they 
categorized them into three groups. The patients were treated with Standard 
Pritchard regime, single loading dose regime and low dose MgSO4 regime 
respectively. Maternal mortality was 7.6% in Pritchard regime and 5% in 
single loading dose. There was no maternal mortality in patients treated with 
low dose regime. 
 
MATERNAL MORBIDITY: 
In this present study, the complication of eclampsia observed in 
patients treated under Dhaka regime were abruption ( 4%), HELLP ( 2%), 
pulmonary edema (10%) and cerebro vascular accidents (2%). In patients  
treated under Pritchard  regime the incidence of abruption and HELLP were 
similar as in Dhaka regime . 4% of patients under Pritchard had pulmonary 
edema. The maternal morbidity between Dhaka regime and Pritchard 
regime was statistically significant.( p <0.05) 
 
 
            
 91 
Shika  seth et al (2010) reported pulmonary edema in patients treated 
with Pritchard regime( 3.8%) and with single loading dose (5%). Cortical 
blindness (5%) reported in patients treated with low dose MgSO4. This 
cortical blindness complication also observed in our present study in a 
patient treated under Dhaka regime.  
According to Knight, United Kingdom Obstetric Surveillance system 
(UKOSS) in 2007 out of 214 eclamptic women 5 women had cerebral 
haemorrhage.     
 
PERINATAL OUTCOME 
 In this present study, among the 100 patients 77 delivered  alive 
babies.Perinatal death occurred in 23 babies.In Dhaka regime 80% babies 
were alive and remaining 20 % died in the perinatal period  In Pritchard 
regime, there was 74% of alive birth  and 13% of perinatal death. Shika seth 
et al (2010) reported  69% live birth , 31% perinatal death in patients treated 
under Pritchard regime. In the same study, they reported 75% live birth and 
25% perinatal death in patients treated under low dose regime. In single 
loadaing dose regime there was 65% of live birth and 35% of perinatal 
death. 
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Gortzaek-Uzen50  and associates (2005) pointed out that MgSO4  will 
cross placenta and  the concentration of Mg in liquor is directly proportional 
to the time of Mg injection.But neonatal depression occurs only in cases of 
magnesium toxicity. None of our babies developed neonatal depression. 
 
Present study  
Dhaka Pritchard 
Shika 
seth et 
al 
Bangal 
et al 
Begum 
et al 
Bissallah 
A Ekele 
et al 
Recurrence 
of fits 2% 2% 8% 6% 1.5% 7.4% 
Maternal 
mortality 2% 2% 7.6% 0% 0% 9.9% 
Maternal 
morbidity 18% 10% 3.8% - - - 
Perinatal  
death 20% 13% 31% - -  
 
 
This present study compared the efficacy of low dose MgSO4 with 
standard Pritchard regime. This study showed that recurence of fits, 
maternal mortality, maternal morbidity and perinatal outcome were not 
statistically significant between Dhaka regime and Pritchard regime. 
Recurrence of fits  in this study is comparable with the Begum et al (1998) 
(2% vs 1.5%). The recurrence of fit is found to be higher  in Shika seth et  
al, Bangal et al and Bissallah A Ekele et al studies.( 8%, 6% and 7.4%) 
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The maternal mortality was nil in Begum et al and in Bangal et al  
studies. The present study observed 2% maternal mortality. This is less than 
the reported mortality of Shika seth et al (7.6%) and  Bissallah A Ekele et al 
(9.9%). 
The maternal morbidity was found to be higher than  in Shika Seth 
study ( 18% vs 3. 8% ). 
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SUMMARY 
 
  In this present study 100 patients of eclamptic women irrespective of 
the type of eclampsia (Antepartum/ Intrapartum/ Postpartum) were included. 
50  patients were treated under  Dhaka regimen. Another 50 eclamptic 
patients were treated  under Pritchard  regime. And the two group of 
patients were observed  for the recurrence of  fits,  maternal morbidity, 
mortality as well as for perinatal outcome. Thus  the safety and efficacy of 
low dose magnesium sulphate was compared with Pritchard’s regimen. 
With respect to seizure recurrence, 2 patients each one from Dhaka and 
Pritchard regime  had recurrent fit. The recurrent seizure patients were 
treated with additional dose of 2g  of 20% MgSO4 Intravenously. There 
were no symptoms of Magnesium toxicity in both the patients. 
 
   In both study and control groups, totally 98 patients  discharged in 
healthy state. Two patients died due to complication. Perinatal outcome of 
patients treated in the two different regime are comparable. The perinatal 
outcome does not differ significantly in both Dhaka and Pritchard regimen 
groups.   
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CONCLUSION 
 
 Most of the Indian women considered to be of low to normal BMI 
need only low dose magnesium sulphate which is sufficient for them  
 Efficacy of low dose MgSO4 regime in controlling the convulsions, 
and its effect on maternal and perinatal outcome is equivalent to 
standard Pritchard regime. 
  Low dose magnesium sulphate is equally  good enough to control 
eclampsia, thereby preventing magnesium toxicity though it is rare 
 Poor manpower and waste of time  in monitoring the Mg toxicity 
symptoms  can be avoided in low dose MgSO4. 
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Any sign of Magnesium toxicity 
Complication during hospital stay 
General condition of mother during discharge-healthy/died 
Fetal outcome 
                    alive 
                    dead 
APGAR score 
Birth weight 
Condition of newborn during discharge  
Healthy/died 
Cause of neonatal death 
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1 Rajathy 20 159433 Primi 2 26 N 1 1 160 100 D 1 1 A  6 _ _ _ 1 1.15 2 
2 Priya 26 158289 Primi 2 34 N 1 1 170 100 D 1 1 S  6 _ _ _ 1 0.95 2 
3 Madhuri 22 162623 Primi 1 38 N 1 1 160 110 P 1 1 V A 6 _ _ _ 1 1.23 1 
4 Kasthuri 22 165029 G2PL1 1 36 N 1 1 170 100 D 1 0 S  1 _ _ _ 1 2 1 
5 Senthamarai 26 167276 Primi 1 37 N 1 1 160 110 P 1 2 V  3 _ _ _ 1 2.7 1 
6 Christura 23 168779 Primi 1 38 N 2 1 150 110 P 1 2 V  4 _ _ _ 1 2.3 1 
7 Chitravalli 23 167568 G2PL1 1 34 N 1 1 170 100 D 1 2 V  4 _ _ _ 1 1.8 2 
8 Shobha 21 168581 Primi 1 41 N 1 1 160 100 D 2 2 O  1 _ _ _ 1 2.8 1 
9 Vasuki 24 168535 Primi 1 28 N 2 2 160 90 P 1 3 V  2 _ _ _ 1 1 1 
10 Amudha 22 169934 Primi 2 35 N 1 1 150 110 D 1 2 V  4 _ _ _ 1 2 1 
11 Latha 30 173396 G2PL1 2 31 N 2 1 130 90 D 1 2 V  2 _ _ _ 1 0.9 1 
12 Rajavalli 24 174543 G2PL1 1 39 N 1 1 150 110 P 1 0 S A 1 _ _ _ 1 2.75 1 
13 Jaseema 22 174454 G2A1 1 38 N 1 1 160 110 D 1 1 S  4 _ _ _ 1 2.2 1 
14 Maheswari 21 174326 Primi 1 37 N 1 1 150 100 P 1 3 V  3 _ _ _ 1 2 1 
15 Saral 30 174637 P1L1 1 26 N 1 1 160 120 D 3 0 A  1 _ _ _ 1 2.3 1 
16 Rashidha 19 176673 Primi 1 44 N 1 1 130 100 D 2 3 S  30 _ _ _ 1 2.8 1 
17 Mahalakshmi 25 177086 Primi 1 35 N 1 1 170 110 D 1 3 V  1 _ _ _ 1 1.5 2 
18 Sathya 23 177125 G2PL1 2 32 N 1 1 150 100 P 1 3 V  6 _ _ _ 1 1.2 2 
19 Sunithra 22 177501 Primi 1 39 N 1 1 150 110 D 1 0 S  1 _ _ _ 1 2.75 1 
20 Deepa 20 177535 Primi 2 29 N 1 1 160 110 P 1 2 V  6 _ _ _ 1 1.25 1 
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21 Meenakshi 28 177320 G2PL1 1 37 N 1 1 150 100 P 1 0 S  1 _ _ _ 1 1 2 
22 Senthamarai 35 177857 G2P10 1 24 N 1 1 160 110 D 1 1 S  6 _ _ _ 1 0.6 1 
23 Nisha 27 177925 G2PL1 1 41 N 1 1 180 130 D 1 1 V  5 _ _ _ 1 2.7 1 
24 Muthu 22 178060 P1L1 2 39 N 1 1 150 90 P 1 0 S  1 _ _ _ 1 3.5 1 
25 Muthulakshm 27 178152 P2L2 1 38 N 1 1 170 110 P 1 0 V  1 _ _ _ 1 2.5 1 
26 Arultherasa 32 178152 G4P3L3 2 38 N 1 1 170 100 D 1 3 S  6 _ _ _ 1 1.9 1 
27 Revathy 21 178343 Primi 1 38 N 1 1 160 110 D 1 1 V  6 _ _ _ 1 3 1 
28 Kalaiarasi 23 178329 P1L2 2 31 N 1 1 150 100 D 1 0 S  1 _ _ _ 1 1.75 2 
29 Joice 23 178827 Primi 2 28 N 10 3 180 110 P 1 1 A  3 1 _ _ 1 1 2 
30 Meena 22 179094 Primi 1 36 N 1 1 150 100 D 1 3 S  2 _ _ _ 1 2.15 1 
31 Sudha 30 179222 Primi 2 32 N 1 1 150 100 P 1 3 S  1 _ _ _ 1 1.5 1 
32 Viji 24 179141 Primi 1 41 N 2 1 160 110 D 1 1 V  2 1 _ _ 1 2.4 1 
33 Rathna 19 179501 G2A1 1 32 N 1 2 110 80 P 1 1 V  8 _ _ _ 1 1.5 1 
34 Ilaveni 14 180201 Primi 2 32 L 6 1 140 90 D 1 2 V  4 _ _ _ 1 1.3 1 
35 Banupriya 19 180745 Primi 1 33 N 1 1 170 110 D 1 1 V  6 _ _ _ 1 1.2 1 
36 Sheelarani 30 180783 G2PL1 1 36 H 1 1 130 90 P 3 0 S  1 _ _ _ 1 2.5 1 
37 Nalini 26 180840 Primi 2 32 N 1 1 150 100 P 1 3 V  2 _ _ _ 1 0.8 1 
38 Latha 22 181318 G2A1 2 37 N 2 1 160 110 P 1 1 V  6 _ _ _ 1 0.75 1 
39 Alageswari 20 183411 Primi 1 39 N 4 1 150 90 D 1 1 V  6 _ _ _ 1 3 1 
40 Umashanthi 30 183714 G2P4 2 38 N 2 1 130 90 D 1 1 V A 3 _ _ _ 1 0.6 1 
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41 Jeyapriya 24 184151 Primi 1 34 H 1 1 160 110 P 1 0 S  2 _ _ _ 1 1.9 1 
42 Revathy 26 184233 Primi 1 30 N 1 1 170 110 P 1 2 S  5 _ _ _ 1 1.8 1 
43 Selvarani 20 184398 G2A1 1 38 H 1 1 150 100 P 1 2 S  1 _ _ _ 1 1.47 1 
44 Kanagavalli 22 185706 P1L1 1 36 O 3 1 160 100 P 3 0 S  7 _ _ _ 1 3 1 
45 Uma 23 185103 Primi 2 28 N 4 1 140 100 D 3 2 V  3 _ _ _ 1 0.7 2 
46 Nithya 20 186514 Primi 1 37 N 1 3 160 100 D 3 0 V  1 _ _ _ 1 2.1 1 
47 Nadhiya 21 182479 Primi 1 38 N 2 1 140 100 D 1 0 S  1 _ _ _ 1 2.5 1 
48 Mahalakshmi 21 187075 Primi 2 36 N 2 1 130 80 D 1 0 S  1 _ _ _ 1 1.7 1 
49 Jeromiya 22 187121 Primi 1 36 N 2 3 180 130 P 1 0 S  1 _ _ _ 1 1.25 2 
50 Balamani 21 187904 Primi 2 37 N 1 1 158 100 D 1 0 S  1 _ _ _ 2 1.55 3 
51 Prabha 22 189114 Primi 1 39 N 2 1 160 110 D 1 0 S  3 _ _ _ 1 3.3 1 
52 Ilaveni 14 180201 Primi 2 37 L 2 2 160 100 D 1 1 V  6 _ _ _ 1 1.3 2 
53 Amudha 30 189305 P6L5 2 37 L 1 1 120 70 D 3 0 V  48 _ _ _ 1 2.3 1 
54 Padmini 20 188023 Primi 1 39 N 1 1 130 100 P 1 0 S  2 _ _ _ 1 3.1 1 
55 Indhumathy 19 189753 Primi 1 36 N 1 1 160 100 D 1 0 V H 1 _ _ _ 1 2.2 2 
56 Leo jancy ma 25 189473 G2A1 2 32 N 2 1 150 110 P 1 0 S  1 _ _ _ 1 1.2 2 
57 Vasugi 25 190357 G2PL1 1 36 N 1 1 130 90 D 3 2 V  4 _ _ _ 1 2.5 1 
58 Malathy 25 190697 Primi 1 37 N 2 1 160 90 D 1 0 S  1 _ _ _ 1 1.2 1 
59 Dhanalakshm 27 191121 G3P2L2 2 39 N 6 1 150 100 P 1 0 V  1 _ _ _ 1 1.3 1 
60 Nadhiya 22 191944 G2PL1 2 34 N 1 1 140 100 D 1 2 V  5 _ _ _ 1 2 1 
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61 Sathyabama 20 192051 G3P2L2 1 37 N 1 1 160 100 P 3 3 S  1 _ _ _ 1 2.5 1 
62 Karpagam 26 192258 G2P1L0 1 37 N 3 1 160 110 P 1 0 S  1 _ _ _ 1 2.3 1 
63 Parimala 21 192364 Primi 1 35 H 1 1 140 100 P 1 1 S  4 _ _ _ 1 1 1 
64 Malathy 21 192371 Primi 1 37 N 3 1 140 100 D 1 _ S  1 _ _ _ 1 2.75 1 
65 Saranya 19 193084 Primi 1 34 N 2 1 160 110 P 3 2 V  4 _ _ _ 1 2 1 
66 Dhavamani 27 193516 Primi 1 35 N 2 1 130 80 P 3 2 V H 2 _ _ _ 1 2 2 
67 UshaNandhin 28 194284 G2PL1 1 34 N 1 1 120 80 D 3 _ S  1.2 _ _ _ 1 1.75 1 
68 Revathy 22 194275 Primi 1 32 N 2 1 150 110 P 1 _ S  3 _ _ _ 1 1.3 1 
69 Rani 20 194350 Primi 2 38 N 3 1 160 100 P 1 _ S  1 _ _ _ 1 14 1 
70 Jeyanthy 24 197044 Primi 2 28 N 2 1 130 90 P 1 1 A  12 _ _ _ 1 1.25 2 
71 Perumayi 24 197020 G2P11 2 37 L 0 1 200 140 D 2 0 V  15 _ _ _ 1 2.54 2 
72 Mariammal 18 196608 Primi 2 34 N 1 1 130 90 P 1 1 S  4 _ _ _ 1 1.2 1 
73 Vasanthi 35 196611 G2P14 1 37 N 0 1 130 90 D 2 0 S  15 _ _ _ 1 3.2 1 
74 Sudha 27 197264 G3A2 1 38 N 1 1 170 110 P 1 12 V  6 _ _ _ 1 1.2 1 
75 Vembu 23 196899 P1L1 2 38 N 1 1 150 90 P 3 0 S  1 _ _ _ 1 3.8 1 
76 Madhuramba 20 196871 Primi 2 32 N 1 1 200 110 D 1 0 S  1 _ _ _ 1 1.3 1 
77 Kayalvizhi 26 198330 Primi 1 38 N 1 2 170 130 D 1 1 S  5 _ _ _ 1 2 1 
78 Kalaivani 22 199472 G2PL1 1 34 N 3 1 140 90 D 1 0 S  1 _ _ _ 1 1.3 1 
79 Kannammal 20 200830 Primi 2 36 N 1 1 130 80 P 1 1 V  7 _ _ _ 1 1.4 1 
80 Ramya 20 202324 Primi 2 34 N 2 1 160 100 P 1 _ S  4 _ _ _ 2 1.6 1 
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81 Radhika 24 202341 Primi 1 33 N 2 1 100 70 P 1 1 V  7 _ _ _ 1 1.6 1 
82 Vaideki 18 203624 Primi 2 28 N 1 1 160 90 D 1 1 A  2 _ _ _ 1 1 1 
83 Jegadhamba 20 203741 G2A1 2 35 0 6 3 190 120 P 1 0 S PE 1.5 1 _ _ 1 1.8 1 
84 Sangeetha 28 203950 G3P2L2 1 38 N 1 1 160 100 P 2 3 V  1.5 _ _ _ 1 2.7 1 
85 Nirosha 23 204083 G2A1 1 40 N 1 1 160 100 P 1 _ S  1 _ _ _ 1 3 KG 1 
86 Vembarasi 28 206262 Primi 1 38 N 1 1 140 90 D 1 2 V  4.5 _ _ _ 2 2.7 1 
87 Malaiyalatha 35 206876 G3A2 1 24 N 1 1 160 100 D 1 2 S  12 _ _ _ 1 750 G 1 
88 Radhika 27 206766 Primi 2 34 N 1 1 150 90 D 1 S S  2 _ _ _ 1 1.85 1 
89 Sheelarani 22 209206 Primi 1 40 N 5 2 150 110 P 1 _ S  2 _ _ _ 1 2.85 1 
90 Rajathi 20 211372 Primi 1 26 N 3 1 200 110 P 1 1 V  6 _ _ _ 1 500G 1 
91 Meenatchi 24 212862 Primi 2 35 N 2 1 170 110 P 1 _ S  4 _ _ _ 1 1.3 1 
92 Chitra 23 213061 Primi 1 37 N 3 2 170 110 D 1 _ S  2 _ _ _ 1 2.5 KG 1 
93 Muthulakshm 22 214365 G3P1L1A1 2 38 N 1 1 90 60 P 1 1 V  5 _ _ _ 1  2 
94 Shanthi 35 216215 G4P3L3 2 37 N 3 1 160 110 D 1 1 V A 3 _ _ _ 1 1.41 1 
95 Parameswari 19 219050 Primi 1 41 N 2 1 130 90 P 1 2 V A 7 _ _ _ 1 3.14 1 
96 Priya 20 23088 Primi 2 34 L 4 2 150 110 D 1 _ S CVA 1 1 _ _ 2 1.8 1 
97 Karthiga 24 230556 Primi 2 37 N 1 1 110 70 P 1 2 S  2 _ _ _ 1 2.6 1 
98 Jegadeeswar 27 230678 Primi 2 35 N 2 1 130 90 P 1 2 S  3 _ _ _ 1 2.66 1 
99 Rajalakshmi 23 280683 Primi 1 36 N 1 1 140 90 D 1 2 S  2 _ _ _ 1 2.76 1 
100 Vijayashanthi 20 233055 Primi 1 35 N 4 2 160 100 P 1 2 V  8 _ _ _ 1 1.2 2 
 
